Jubo Wang

Jiangsu Key Laboratory Of Drug Design And Optimization, P.R. China
Nanjing, 211198, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability.

Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability.

Journal: Journal of medicinal chemistry

Published: March 20, 2026

Wogonin-derived chemotype enables discovery of novel GLS1 inhibitors with potent antitumor activity.

Wogonin-derived chemotype enables discovery of novel GLS1 inhibitors with potent antitumor activity.

Journal: Future medicinal chemistry

Published: March 12, 2026

Correction to "Design, Synthesis, and Biological Evaluation of Sulfonamide Derivatives as Potent CDK9 Inhibitors".

Correction to "Design, Synthesis, and Biological Evaluation of Sulfonamide Derivatives as Potent CDK9 Inhibitors".

Journal: ACS medicinal chemistry letters

Published: September 27, 2025

Design, Synthesis, and Biological Evaluation of Sulfonamide Derivatives as Potent CDK9 Inhibitors.

Design, Synthesis, and Biological Evaluation of Sulfonamide Derivatives as Potent CDK9 Inhibitors.

Journal: ACS medicinal chemistry letters

Published: July 15, 2025

Cancer Biology of GSPT1: Mechanisms and Targeted Therapy Opportunities of Molecular Glue Degraders.

Cancer Biology of GSPT1: Mechanisms and Targeted Therapy Opportunities of Molecular Glue Degraders.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: June 27, 2025

Design and Discovery of Preclinical Candidate LYG-409 as a Highly Potent and Selective GSPT1 Molecular Glue Degraders.

Design and Discovery of Preclinical Candidate LYG-409 as a Highly Potent and Selective GSPT1 Molecular Glue Degraders.

Journal: Journal of medicinal chemistry

Published: January 24, 2025

STNGS: a deep scaffold learning-driven generation and screening framework for discovering potential novel psychoactive substances.

STNGS: a deep scaffold learning-driven generation and screening framework for discovering potential novel psychoactive substances.

Journal: Briefings in bioinformatics

Published: September 25, 2024

Inhibitors and PROTACs of CDK2: challenges and opportunities.

Inhibitors and PROTACs of CDK2: challenges and opportunities.

Journal: Expert opinion on drug discovery

Published: July 12, 2024

Development of MPS1 Inhibitors: Recent Advances and Perspectives.

Development of MPS1 Inhibitors: Recent Advances and Perspectives.

Journal: Journal of medicinal chemistry

Published: December 14, 2023

Discovery of Selective and Potent Macrocyclic CDK9 Inhibitors for the Treatment of Osimertinib-Resistant Non-Small-Cell Lung Cancer.

Discovery of Selective and Potent Macrocyclic CDK9 Inhibitors for the Treatment of Osimertinib-Resistant Non-Small-Cell Lung Cancer.

Journal: Journal of medicinal chemistry

Published: October 23, 2023

Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective.

Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective.

Journal: Medicinal research reviews

Published: September 20, 2023

A patent review of selective CDK9 inhibitors in treating cancer.

A patent review of selective CDK9 inhibitors in treating cancer.

Journal: Expert opinion on therapeutic patents

Published: May 02, 2023

Showing 1-12 of 31

Last Updated: 09/26/2026